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RESEARCH ARTICLE
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Abstract
Objective/background: Data generated from retrospective studies on primary mediastinal B-cell lymphoma (PMBCL)
outcome are valuable as no prospective phase 3 trials have been conducted in this rare type of lymphoma.
Methods: Our goal was to assess the long-term outcome of 41 patients with PMBCL who were treated at the Kuwait
Cancer Center. We evaluated two types of multidrug treatment, R-CHOP (rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisone) and DA-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin,
and rituximab), and determined overall survival and complete response (CR) as primary endpoints.
Results: In our cohort, 27 (66%) cases were treated with R-CHOP and 14 (34%) cases were treated with DA-EPOCH-R.
The overall median follow-up time was 34 months. Among the patients treated with R-CHOP, 23 out of 27 (92.6%)
patients achieved CR; similarly, 10 out of 14 patients (85.7%) in the DA-EPOCH-R group achieved CR after initial
treatment. There were no differences in OS between patients treated with R-CHOP versus DA-EPOCH-R.
Conclusion: The ﬁndings of this study indicate that combined chemotherapy and immunotherapy results in excellent
long-term outcome of patients with PMBCL. At our center, we prefer R-CHOP to DA-EPOCH-R for low-risk patients
with nonbulky disease.
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1. Introduction

P

rimary mediastinal (thymic) B-cell lymphoma
(PMBCL) is an aggressive cancer of thymic
origin that arises predominantly in the mediastinum
[1]. PMBCL accounts for 2e3% of all non-Hodgkin
lymphomas and is mainly reported in young adults
(mean age, 35 years). PMBCL typically presents as a
bulky mass localized in the anterosuperior mediastinum with frequent invasion of lungs, pleura, and
pericardium, and involvement of the supraclavicular and cervical lymph nodes [2e4]. With

disease progression, distant sites such as kidney,
adrenal glands, liver, and central nervous system
can be involved, although there is typically no bone
marrow involvement. Many clinical and biological
factors have been recognized as prognostic markers
for this disease [4].
Currently, there is no consensus with respect to
the best treatment options for this disease. PMBCL
is typically treated with combination chemoimmunotherapy; however, the role of radiotherapy
(RT) with respect to this disease remains unclear
[3,5]. Furthermore, an ideal chemoimmunotherapy

Abbreviations: CI, conﬁdence interval; CR, complete response; DA-EPOCH-R, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; OS,
overall survival; PFS, progression-free survival; PMBCL, primary mediastinal B-cell lymphoma; R-CHOP, rituximab, vincristine,
doxorubicin, cyclophosphamide, and prednisone; R-IPI, revised international prognostic scoring system; RT, radiotherapy.
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protocol has not yet been identiﬁed. Among the
critical issues, there are questions as to whether the
use of an intense chemotherapy regimen with
immunotherapy would eliminate the need for local
RT as consolidative treatment, and the issue has not
been addressed in a prospective randomized phase
3 trial. However, a prospective phase 2 study by
Dunleavy et al. [6] suggested the possibility of
eliminating RT in patients treated with the doseadjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DAEPOCH-R) regimen. In this retrospective study, we
evaluated the outcomes of patients with PMBCL
who were reviewed and treated at our center with
respect to both the chemoimmunotherapy protocol
used and the clinical impact of subsequent local RT.

2. Materials and methods
We enrolled 41 patients with PMBCL who were
seen at our lymphoma clinics between December
2008 and December 2018. A diagnosis of PMBCL
was based on World Health Organization guidelines
[1]. PMBCL was histopathologically deﬁned by
sheets, consisting of medium to large cells with
abundant eosinophilic to pale cytoplasm and ovoid
nuclei, separated by prominent collagenous ﬁbrosis.
Occasionally, pleomorphic multilobed nuclei reminiscent of ReedeSternberg cells were noted. The
tumor cells of patients enrolled in our study were
CD20-, CD79a-, BCL2-, BCL6-, and MUM1-positive,
and were also notable for the distinct expression of
CD23 and CD30, unlike what is observed in cases of
diffuse large B-cell lymphoma. The absence of
EpsteineBarr virus and strong positivity for PAX5,
BOB1, and OCT2 distinguished these cells from
ReedeSternberg cells, which are characteristic of
classical Hodgkin’s lymphoma [1].
Our institutional staging procedure included a
detailed history and physical examination, complete
blood count, and serum chemistry determinations
including lactate dehydrogenase (LDH), as well as a
bone marrow examination. Patients also underwent
computed tomographyepositron emission tomography scanning at the time of diagnosis as well as
during and after completion of treatment. The
multidrug R-CHOP protocol included cyclophosphamide (750 mg/m2), adriamycin (50 mg/m2),
vincristine (1.4 mg/m2; 2 mg limit), and prednisone
(100 mg) for 5 days [7] and anti-CD20 antibody
(rituximab; brand name: MabThera) at a dose of 375
mg/m2 on Day 1 of each cycle. The DA-EPOCH-R
regimen included a continuous intravenous infusion
of etoposide (50 mg/m2/d on Days 1e4), oral prednisone (60 mg/m2/d on Days 1e5), continuous

Table 1. Patient demographics and clinical characteristics.
Characteristics

n (%)

Age (y), median (range)
Sex
Male
Female
B symptoms
Yes
No
Stage
I/II
III/IV
LDH
Normal
<300 IU high
Treatment chemotherapy
R-CHOP
DA-EPOCH-R
Received radiotherapy

30 (17e77)
20 (49)
21 (51)
18 (44)
23 (56)
22 (54)
19 (46)
16 (40)
24 (60)
27 (66)
14 (34)
16 (39)

Note. LDH ¼ lactate dehydrogenase; R-CHOP ¼ rituximab,
vincristine, doxorubicin, cyclophosphamide, and prednisone; RDA-EPOCH ¼ etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab.

infusion of vincristine (0.4 mg/m2/d on Days 1e4),
intravenous administration of cyclophosphamide
(750 mg/m2/d) over 15 minutes on Day 5, continuous infusion of doxorubicin (10 mg/m2/d on Days
1e4), anti-CD20 antibody (rituximab; MabThera,
Hoffman-la Roche) at a dose of 375 mg /m2 on Day
1, and subcutaneous administration of ﬁlgrastim (5
mg/kg) from Day 6, until an absolute neutrophil
count of 10  109/L was reached [7,8]. All statistical
analysis was performed using STATA version 16
(Stata Corp., College Station, TX, USA). Nonparametric variables were compared using the
ManneWhitney U test, the Fisher exact test, or the
chi-square test as appropriate. The KaplaneMeier
method and the long-rank test were used to determine the signiﬁcance of differences in overall survival (OS) and progression-free survival (PFS). OS
was deﬁned as the time from the beginning of
treatment to the time of death, whereas PFS was
deﬁned as the time from the beginning of treatment
to the time of death or disease progression. For each
variable, the hazard ratio and 95% conﬁdence interval (95% CI) were estimated. Statistical signiﬁcance was set at p < .05. This study was approved by
the institutional ethics committee.

3. Results
The characteristics of our patient cohort are
shown in Table 1. A total of 41 patients diagnosed
with PMBCL were recruited, consisting of 21 (51%)
females and 20 (49%) males. The median age was 30
(range 15e77) years overall, with a median age and
standard deviation (SD) of 29 ± 6.9 and 31 ± 13.6
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Table 2. PMBCL Cases Distributed According to Treatment Type and RIPI.
R-IPI score

R-CHOP,
n (%)

R-DA-EPOCH,
n (%)

0
1 or 2
3, 4, 5

3 (7.3)
20 (48.7)
4 (9.7)

0
10 (24.3)
4 (9.7)

Note. R-CHOP ¼ rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisone; R-DA-EPOCH ¼ etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab;
R-IPI ¼ revised international prognostic index.

years for females and males, respectively. In the
majority of cases, the presenting symptom was
shortness of breath. Systemic B symptoms of fever,
night sweats, and/or weight loss were reported in 28
(44%) patients, and serum LDH was elevated (>300
IU/L) in 24 (60%) cases. OS of the entire cohort was
not reached (Fig. 1).
Regarding treatment regimen, 27 (66%) patients
were treated with R-CHOP and 14 (34%) patients
were treated with DA-EPOCH-R. Using the revised
international prognostic scoring system (R-IPI) of
age > 60 years, high LDH (>300 IU/L), >1 extranodal
site, cancer stage III/IV, and Eastern Cooperative
Oncology Group (ECOG) Grade > 2, we found that
56% of patients in the R-CHOP arm had a favorable
risk score (score of 0, 1, or 2) compared to 24.3% of
patients in the DA-EPOCH-R arm. We also found
that there were four high-risk cases (score  3) in
both arms (Table 2).
The overall median follow-up time was 34
months; the median follow-up time was 30 (range

6e110) months among those treated with R-CHOP
and 13 (range 3e83) months for those treated with
DA-EPOCH-R. Among those in the R-CHOP group,
23 of the 27 (92.6%) patients achieved complete
remission (CR), whereas 10 out of 14 (85.7%) cases of
those in the DA-EPOCH-R group achieved CR after
initial treatment. Consolidative RT was administered to 15 (56%) patients treated with R-CHOP,
most of whom had a bulky mediastinal mass (10
cm in diameter), but only one patient treated with
DA-EPOCH-R received RT. The median dose of RT
was 30 Gy. Patients with low-risk R-IPI scores tended to do better; however, there was no statistical
difference between risk groups (Fig. 2).
Over a median follow-up period of 34 (range
17e77) months, we found no differences in OS in a
comparison between R-CHOP- and DA-EPOCH-Rtreated patients (Fig. 3); furthermore, differences in
median survival for each group did not reach statistical signiﬁcance, with OS ranging between
92e112 and 46e87 months, respectively ( p ¼ .26).
We also found that in the R-CHOP group, those
patients with a low R-IPI score tended to do better
than high-risk cases; however, a larger number of
cases is needed for proper statistical evaluation.

4. Discussion
PMBCL is an uncommon form of lymphoma that
represents only 3e5% of all lymphoid malignancies
seen at our institution. Patients in our cohort
responded positively to treatment; in fact, most
achieved CR in response to one of two

Fig. 1. Overall survival (OS) in primary mediastinal lymphoma patients in the entire analyzed group.
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Fig. 2. R-IPI risk group survival in all cohort (group 1 ¼ 0 score, group 2
¼ 1 or 2 scores, group 3 ¼ 3 or more scores), no signiﬁcant differences
between the groups. R-IPI ¼ revised international prognostic scoring
system.

chemoimmunotherapy protocols. To date, there
have been few prospective studies that focused
speciﬁcally on PMBCL. Although some previous
studies have suggested that PMBCL is an aggressive
lymphoma associated with poor outcome [9,10],
immunotherapy has provided a new perspective on
this disease. Furthermore, more recent studies are
notable for the improved outcomes observed in
response to combined chemoimmunotherapy and
RT [8,11].
In our cohort, we found no statistically signiﬁcant
differences with respect to OS between the response
of those treated with R-CHOP to those treated with
DA-EPOCH-R. However, we found that those cases
deemed high-risk based on an international prognostic score fared worse. Prior to the advent of
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immunotherapy, patients diagnosed with PMBCL
were treated with CHOP alone followed by routine
mediastinal RT [12,13]. However, patients with
nonbulky disease (mediastinal mass diameter < 10
cm) who were treated with R-CHOP without local
RT tended to respond positively as well.
A recent clinical study revealed that RT can be
omitted in patients undergoing intense chemoimmunotherapy with DA-EPOCH-R [6,14]. However, this study was a prospective phase 2 study with
no comparator group. Furthermore, the study
included 16 cases from another center that had
signiﬁcantly less extranodal disease [14]; this factor
alone contributes to a favorable outcome. Although
it is clearly effective, DA-EPOCH-R is administered
as a 4-day intravenous infusion, a factor that may be
difﬁcult to accommodate in a day-care hospital or
even in an inpatient setting. Moreover, the toxicity
proﬁle of this combination is higher than that of RCHOP, and as a result, all patients undergoing this
protocol require hospital admission, including at
our institution. Furthermore, the long-term
sequelae of DA-EPOCH-R, such as infertility and
second malignancies, also need to be considered.
In conclusion, the prognosis of patients with
PMBCL has most certainly improved, with high
rates of CR and OS documented in several recent
observational and retrospective studies. Admittedly,
there is currently no consensus on the ideal chemoimmunotherapy protocol as well as the need for
subsequent local RT consolidation therapy; nevertheless, there is evidence that a combination of these
two modalities appears to be highly effective. CHOP
chemotherapy has stood the test of time, and is

Fig. 3. Overall survival in accordance with chemotherapy protocol administered.
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widely used among physicians who treat patients
with lymphoma. Furthermore, a recent phase 3
clinical trial that compared the impact of DAEPOCH-R with R-CHOP and included a small
cohort of patients with primary mediastinal lymphoma revealed no signiﬁcant differences with
respect to PFS or OS [15], a ﬁnding which was also
consistent with that of a recent retrospective study
by Malenda et al. [16]. In addition, among those
intense regimens used for aggressive lymphomas,
R-CHOP appears to be not only the most well
tolerated, but also associated with the least toxicity
[15]. Our study is limited by the fact it is retrospective. The included cases coming from different
time periods, and data retrieval solely relayed on
medical records.
At our center, we prefer to use R-CHOP as
opposed to DA-EPOCH-R in low-risk patients with
nonbulky disease (mass < 10 cm) because we found
that these cases fared well with R-CHOP alone
while avoiding intense regimen toxicity and the
need for frequent admission. We also consider the
possibility that checkpoint inhibitors may have a
role in the treatment of PMBCL, particularly, in
cases of relapse or refractory disease. A clinical trial
addressing this novel approach is most certainly
warranted.
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